Springer Seminars in Immunopathology

, Volume 20, Issue 3–4, pp 375–387 | Cite as

Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders

  • Tanzina Haque
  • Dorothy H. Crawford
Article

Keywords

Internal Medicine Lymphoproliferative Disorder Recipient Type 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alfrey EJ, Friedman AL, Grossman RA, Perloff LJ, Naji A, Barker CF, Montone KT (1992) A recent decrease in the time to development of monomorphous and polymorphous post-transplant lymphoproliferative disorder. Transplantation 54:250PubMedGoogle Scholar
  2. 2.
    Armitage JM, Kormos RL, Stuart S, Fricker FJ, Griffith BP, Nalesnik M, Hardesty RL, Dummer JS (1991) Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporin-based immunosuppression. J Heart Lung Transplant 10:877PubMedGoogle Scholar
  3. 3.
    Baer R, Bankier AT, Biggin MD, Deninger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Sequin G, Tuffnell PS, Barrell BG (1984) DNA sequence and expression of the B958-Epstein-Barr virus genome. Nature 310:207PubMedGoogle Scholar
  4. 4.
    Beveridge T, Krupp P, McKibbin C (1984) Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1:788Google Scholar
  5. 5.
    Birkeland SA (1983) Cancer in cadaver kidney transplant patients. Surgery 93:504PubMedGoogle Scholar
  6. 6.
    Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W (1995) Specific cytotoxic T lymphocytes recognise the immediate early transactivator Zta of Epstein-Barr virus. J Virol 69:4872PubMedGoogle Scholar
  7. 7.
    Bourgault I, Gomez A, Gomard E, Levy JP (1991) Limiting dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 84:501PubMedGoogle Scholar
  8. 8.
    Burman K, Crawford DH (1991) Effect of FK506 on Epstein-Barr virus specific cytotoxic T cells. Lancet 337:297PubMedGoogle Scholar
  9. 9.
    Callan MFC, Steven N, Krausa P, Wilson JDK, Moss PAH, Gillespie, Bell JI, Rickinson AB, McMichael AJ (1996) Large clonal expansion of CD8+T cells in acute mononucleosis. Nat Med 2:906PubMedGoogle Scholar
  10. 10.
    Cen H, Breinig MC, Atchison RW, Ho M, McKnight JLC (1991) Epstein-Barr virus transmission via the donor organ in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4. J Virol 65:976PubMedGoogle Scholar
  11. 11.
    Cox KL, Lawrence-Miyasaki, Garcia-Kennedy, Lennette ET, Martinez OM, Krams SM, Brequist WE, Esquivel CO (1995) An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59:524PubMedGoogle Scholar
  12. 12.
    Crawford DH, Epstein MA, Bornkamn GW, Achong BG, Finerty S, Thompson JL (1980) Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in a patient with renal allograft. Lancet 1:1355PubMedGoogle Scholar
  13. 13.
    Epstein MA, Crawford DH (1998) Gamma-herpes-viruses: Epstein-Barr virus. In: Collier L, Balows A, Sussman M (eds) Topley and Wilson's microbiology and microbial infections, 9th edn, vol 1. Arnold, London, pp 351–366Google Scholar
  14. 14.
    Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I (1988) Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693PubMedGoogle Scholar
  15. 15.
    Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH, Simmons RL, Najarian JS (1982) Acyclovir therapy and transition from polyclonal to monoclonal B cell proliferation. N Engl J Med 306:913PubMedGoogle Scholar
  16. 16.
    Haque T, Thomas JA, Falk K, Parratt R, Hunt B, Yacoub M, Crawford DH (1996) Transmission of donor Epstein-Barr virus in transplanted organ causes lymphoproliferative diseases in recipient. J Gen Virol 77:1169PubMedGoogle Scholar
  17. 17.
    Haque T, Thomas JA, Parratt R, Hunt B, Yacoub M, Crawford DH (1997) A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation 64:1028PubMedGoogle Scholar
  18. 18.
    Haque T, Amlot P, Helling N, Thomas JA, Sweny P, Rolles K, Burroughs A, Prentice HG, Crawford DH (1998) Restoration of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 160:6204PubMedGoogle Scholar
  19. 19.
    Henle G, Henle W (1979) The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG (eds) The Epstein-Barr virus. Springer, Berlin Heidelberg New York, pp 297–320Google Scholar
  20. 20.
    Henle G, Henle W, Diehl W (1968) Relation of Burkitt's tumour-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 59:94PubMedGoogle Scholar
  21. 21.
    Ho M, Miller G, Wayne A, Breinig M, Dummer J, Andiman W, Starzl T, Eastman R, Griffith BP, Hardesty R, Bahnson H, Hakala T, Rosenthal J (1985) Epstein-Barr virus infection and DNA hybridisation studies in post-transplant lymphomas and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152:876PubMedGoogle Scholar
  22. 22.
    Ho M, Jaffe R, Miller G, Breinig MK, Dummer IS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative disease after transplantation and its manifestations in children. Transplantation 45:719PubMedGoogle Scholar
  23. 23.
    Kieff E (1996) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 3rd edn. Lippincott-Raven, Philadelphia, pp 2343–2396Google Scholar
  24. 24.
    Kino T, Hatanaka H, Miyata S (1987) FK-506, a novel immunosuppressant isolated from Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40:1256Google Scholar
  25. 25.
    Kroes ACM, Brouwer ML, Batenburg M van, Balk AHMM (1991) Primary Epstein-Barr virus (EBV) infection in an immunosuppressed patient: symptoms, serology and T cell response. J Infect Dis 163:1385PubMedGoogle Scholar
  26. 26.
    Levitskaya J, Coram M, Levitsky V, hutch S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature 375:685PubMedGoogle Scholar
  27. 27.
    Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA (1995) A novel form of Epstein-Barr virus latency in normal B cells. Cell 80:593PubMedGoogle Scholar
  28. 28.
    Moss DJ, Wallace LE, Rickinson AB, Epstein MA (1981) Cytotoxic T cell recognition of Epstein-Barr virus infected B cells. I: specificity and HLA-restriction of effector cells reactivated in vitro. Eur J Immunol 11:686PubMedGoogle Scholar
  29. 29.
    Murray RJ, Kurilla SR, Moss DJ, Griffith HM, Brooks JM, Mackett M, Arrand JR, Rowe M, Burrows SR, Moss DJ, Kieff E (1990) Human cytotoxic T cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci USA 87:2906PubMedGoogle Scholar
  30. 30.
    Nalesnik MA (1990) Involvement of the gastrointestinal tract by Epstein-Barr virus-associated posttransplant lymphoproliferative disorders. Am J Surg Pathol 14:92PubMedGoogle Scholar
  31. 31.
    Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am J Pathol 133:173PubMedGoogle Scholar
  32. 32.
    Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514PubMedGoogle Scholar
  33. 33.
    Papadopoulos EB, Ladanyi M, Emanuel D (1994) Infusions of donor leukocytes to treat Epstein-Barr-virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185PubMedGoogle Scholar
  34. 34.
    Penn I, Porat G (1995) Central nervous system lymphomas in organ allograft recipients. Transplantation 59:240PubMedGoogle Scholar
  35. 35.
    Perera SM, Johannessen I, Thomas JA, Brooks LA, N'Jie Jobe J, Crawford DH (1997) Growth of Epstein-Barr virus-associated B lymphoproliferative disease tissue in a severe combined immunodeficient mouse. Blood 88:1123Google Scholar
  36. 36.
    Perera SM, Thomas JA, Burke M, Crawford DH (1998) Analysis of the T cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol 184:177PubMedGoogle Scholar
  37. 37.
    Pope JH, Horne MK, Scott W (1968) Transformation of human foetal leucocytes in vitro by infiltrates of a human leukaemia cell line containing herpes-like virus. Int J Cancer 3:857PubMedGoogle Scholar
  38. 38.
    Randhawa PS, Yousem SA, Paradis IL, Dauber JA, Griffith BP, Locker J (1989) The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heartlung transplant recipients. Am J Clin Pathol 92:177PubMedGoogle Scholar
  39. 39.
    Renard TH, Andrews WS, Foster ME (1991) Relationship between OKT3 administration, EBV seroconversion and the lymphopriliferative syndrome in pediatric liver transplant recipients. Transplant Proc 23:1473PubMedGoogle Scholar
  40. 40.
    Rocchi G, Felici AD, Ragona G, Heinz A (1977) Quantitative evaluation of Epstein-Barr virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med 296:132PubMedGoogle Scholar
  41. 41.
    Rooney CM, Smith CA, Ng CYC (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9PubMedGoogle Scholar
  42. 42.
    Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of paediatric transplant patients and risk of lymphoproliferative disease. Blood 9:2715Google Scholar
  43. 43.
    Sixbey JW, Vesterinen EH, Nedrud JG, Raab-Traub N, Walton LA, Pagano IS (1983) Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 306:480PubMedGoogle Scholar
  44. 44.
    Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS (1984) Epstein-Barr-virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225PubMedGoogle Scholar
  45. 45.
    Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234PubMedGoogle Scholar
  46. 46.
    Starzl TF, Proter DA, Iwatusuki S (1984) Reversibility of lymphomas or lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583PubMedGoogle Scholar
  47. 47.
    Stevens NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185:1605PubMedGoogle Scholar
  48. 48.
    Tierney RJ, Steven N, Young LS, Rickinson AB (1994) Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374PubMedGoogle Scholar
  49. 49.
    Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH (1990) Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49:292Google Scholar
  50. 50.
    Thomas JA, Crawford DH, Burke M (1995) Clinicopathological implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol 48:287PubMedGoogle Scholar
  51. 51.
    Tsoukas CD, Carson DA, Fong S, Vaughan JH (1982) Molecular interactions in human T cell-mediated cytotoxicity to EBV 11. Monoclonal antibody OKT3 inhibits a post-killer recognition/adhesion step. J Immunol 129:1421PubMedGoogle Scholar
  52. 52.
    Van Gelder T, Kroes LCM, Mulder A, Gratama JW, Weimer W (1994) A living-related kidney donor as the source of a nearly fatal primary Epstein-Barr virus infection following transplantation. Transplantation 58:852PubMedGoogle Scholar
  53. 53.
    Veronese ML, Veronesi A, D'Andrea E, Mistro ARD, Indraccol S, Mazza MR, Mion M, Zamarchi R, Menin C, Panozzo M, Amadori A, Chieco-Bianchi L (1992) Lymphoproliferative disease in human peripheral blood mononuclear cell-injected scid mice. I. T lymphocyte requirement for B cell tumour generation. J Exp Med 176:1763PubMedGoogle Scholar
  54. 54.
    Wallace CE, Rickinson AB, Rowe M, Epstein MA (1982) Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 297:413PubMedGoogle Scholar
  55. 55.
    Weiss LM, Movahed LA (1989) In situ demonstration of Epstein-Barr viral genomes in viral-associated B lymphoproliferation. Am J Pathol 134:651PubMedGoogle Scholar
  56. 56.
    Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB (1989) Epstein-Barr virus immortalised B-cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 43:67PubMedGoogle Scholar
  57. 57.
    Young L, Alfieri C, Hennesy K (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 321:1080PubMedGoogle Scholar
  58. 58.
    Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • Tanzina Haque
    • 1
  • Dorothy H. Crawford
    • 1
  1. 1.Department of Medical MicrobiologyThe University of Edinburgh Medical SchoolEdinburghUK

Personalised recommendations